logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10774092 B1

PDFFull Text
Date of Patent:
Sep. 15, 2020

Filed:

Apr. 19, 2019

Ulk1 inhibitors and methods using same

Applicants:

Salk Institute for Biological Studies, La Jolla, CA (US);

Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US);

Yale University, New Haven, CT (US);

Inventors:

Reuben J. Shaw, La Jolla, CA (US);

Daniel F. Egan, La Jolla, CA (US);

Nicholas Cosford, La Jolla, CA (US);

Benjamin Turk, New Haven, CT (US);

Mitchell Vamos, La Jolla, CA (US);

Dhanya Raveendra Panickar, La Jolla, CA (US);

Matthew Chun, La Jolla, CA (US);

Douglas Sheffler, La Jolla, CA (US);

Assignees:

SALK INSTITUTE FOR BIOLOGICAL STUDIES, La Jolla, CA (US);

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, La Jolla, CA (US);

YALE UNIVERSITY, New Haven, CT (US);

Attorney:

Wilson Sonsini Goodrich & Rosati

Primary Examiner:

Zohreh A Fay

Int. Cl.
CPC ...
A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/5383 (2006.01); A61K 31/5377 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 239/42 (2006.01); C12Q 1/48 (2006.01); C07D 498/04 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 239/48 (2006.01); C07D 239/557 (2006.01); C07D 471/04 (2006.01); A61K 45/06 (2006.01); C07D 239/34 (2006.01); C07D 239/47 (2006.01); C07K 7/08 (2006.01);
U.S. Cl.
CPC ...
C07D 498/04 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 45/06 (2013.01); C07D 239/34 (2013.01); C07D 239/42 (2013.01); C07D 239/47 (2013.01); C07D 239/48 (2013.01); C07D 239/557 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07K 7/08 (2013.01); C12Q 1/485 (2013.01); C12Y 207/11001 (2013.01); G01N 2333/912 (2013.01); G01N 2500/04 (2013.01); G01N 2500/20 (2013.01); G01N 2800/52 (2013.01);
Abstract

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Find Patent Forward Citations

Loading…